denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Adult, Clinical Practice (Health Services and Quality), Elderly, Clinical Research, Health outcomes research, Education, Diseases, Therapy sequence, Real-world evidence, Thrombotic disorders, Treatment Considerations, Young adult , Human, Study Population
Objectives: To develop a thrombotic microangiopathy (TMA) Team and implement a TTP Pathway to improve TTP care by reducing TTP relapse or TTP-related death (TTP-RRD) at a rural, Appalachian, tertiary medical center.
Methods: Prospective quality improvement project using the DMAIC (Define, Measure, Analyze, Improve, Control) methodology to develop a multi-disciplinary TMA team and a TTP Pathway. The TMA team comprised Hematology, Nephrology, Laboratory Medicine, and Pharmacy members who guided the Hematology/Oncology consult service. Pathway care included standardized plasma exchange (PEX), rituximab, caplacizumab, improved coordination between medical services, and regular outpatient biochemical TTP surveillance. TMA outcomes were determined by retrospective chart review for patients with acute TTP treated with usual care (N=16) and the TTP Pathway (N=16) between 2016 and 2023.
Results and conclusions: Patients were predominantly women (63.2%), Caucasian (88.5%), located far (85%) from the medical center and low-income (46.2%) based on insurance. All patients had acquired TTP. TTP-RRD at 90 days was reduced from 56% with usual care to 6% with Pathway care (95% CI 0.23 to 0.77, P=0.022); TTP relapse alone at 90 days was reduced from 50% to 0% (95% CI 0.26 to 0.74, P= 0.0011) with TTP Pathway care. On Kaplan Meier analysis, TTP-RRD was significantly lower throughout the intervention with TTP Pathway care (P=0.018). With TTP Pathway, the duration of PEX increased (median 6 vs 12 sessions, P<0.05), as did the usage of rituximab (31.3% vs 93.8%, 95% CI -0.36 to -0.88, P=0.003) and caplacizumab (6.3% vs 62.5%, 95% CI -.027 to -0.81, P=0.001). All TTP Pathway patients underwent biochemical surveillance in remission, and 31% of patients had pre-emptive rituximab to reduce the possibility of clinical relapse.
This study shows that a TMA team utilizing a protocol-based TTP Pathway can reduce TTP morbidity and improve care for this rare hematologic disease. This approach can improve the care of other multisystem hematologic diseases.
Disclosures: No relevant conflicts of interest to declare.